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IMPORTANCE The p.Gln368Ter (rs74315329) risk allele in themyocilin gene (MYOC) was
initially reported to have high penetrance in glaucoma registry-based studies, but much lower
estimates were recently obtained from population-based studies. We investigated this
disparity using data from Australia and the United Kingdom.
OBJECTIVES To examine the penetrance and effect size of theMYOC p.Gln368Ter variant with
glaucoma and ocular hypertension (OHT).
DESIGN, SETTING, AND PARTICIPANTS This cross-sectional studywithin the UK Biobank
(UKBB) included participants of white British ancestry. Glaucoma cases were defined by
International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10)
diagnoses and self-reported questionnaires. Carriers of theMYOC p.Gln368Ter variant were
identified using genotype imputation from arrays. In contrast, 2 Australian registry-based
studies, the Australian and New Zealand Registry of Advanced Glaucoma and the Glaucoma
Inheritance Study in Tasmania, ascertained glaucoma cases referred by eye care clinicians,
with historic control participants recruited from other Australian studies. Samples were either
directly sequenced or had genotypes determined by imputation (for the Australian registry
and historic control participants). Recruitment to the UKBB occurred between 2006 and
2010, and data analysis occurred from September 2017 to July 2018.
MAIN OUTCOMES ANDMEASURES The penetrance and odds ratio (OR) were estimated for the
MYOC p.Gln368Ter variants in participants with glaucoma and OHT.
RESULTS A total of 411 337 UKBB participants of white British ancestry (mean [SD] age,
56.6 [8.0] years) were included, plus 3071 Australian registry and 6750 historic control
participants. In the UKBB, theminor allele frequency of theMYOC p.Gln368Ter variant was 1
in 786 individuals (0.13%). The odds ratio of p.Gln368Ter in patients with primary open-angle
glaucoma (POAG) was 6.76 (95% CI, 4.05-11.29); glaucoma (POAG, self-reported glaucoma,
and unspecified glaucoma), 4.40 (95% CI, 3.38-5.71); OHT, 3.56 (95% CI, 2.53-4.92); and
OHT and glaucoma combined, 4.18 (95% CI, 3.05-5.67). The penetrance of theMYOC
p.Gln368Ter variant was 7.6% in patients with glaucoma, 24.3% in patients with OHT, and
30.8% in patients with OHT and glaucoma combined. In the Australian registry studies, the
odds ofMYOC p.Gln368Ter variant were 12.16 (95% CI, 6.34-24.97) in patients with advanced
glaucoma and 3.97 (95% CI, 1.55-9.75) in those with nonadvanced glaucoma; the penetrance
of glaucomawas 56.1%, and penetrance in those considered to have glaucoma or be
glaucoma suspects was 69.5%.
CONCLUSIONS AND RELEVANCE TheMYOC p.Gln368Ter variant confers a very high-risk effect
size for advanced glaucoma; the risk is lower in nonadvanced glaucoma and OHT. In the
general population sample, approximately 50% ofMYOC p.Gln368Ter carriers 65 years and
older had glaucoma or OHT, with higher prevalence in the Australian registry studies.
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G laucoma is the leading cause of irreversible blindnessglobally. Themost common formsof glaucomaarepri-maryopen-angleglaucoma (POAG)andprimaryangle-
closure glaucoma (PACG). For the population older than 40
years, the worldwide age-standardized prevalence of glau-
coma is 3.54%; for POAG and PACG, it is 3.05% and 0.50%,
respectively.1 It is estimated there were 60.5 million patients
withPOAGandPACGworldwide in2010, and thatnumberwill
be 112million by 2040.1,2 Elevated intraocular pressure (IOP)
is the major modifiable risk factor for POAG. Progression of
POAG is arrested or reduced if the IOP is lowered by 30% to
50% from baseline levels.3
Genetic factorsplayan important role inglaucoma.4-6Hav-
ing a first-degree relativewith glaucoma raises the likelihood
of developing glaucoma by 9.4-fold relative to the general
population.7 A recent large-scale study estimated the herita-
bility of glaucoma tobe70%using reconstructed familydata.8
Themyocilingene (MYOC) at theGLC1A locuswas the firstgene
discovered to be associated with POAG.9,10 Pathogenic vari-
ants inMYOChavebeen found in2%to4%of individualswith
POAG.11,12Theexactpathogenicmechanismsbywhichdisease-
causingvariants inMYOCmight causeglaucomahavenotbeen
elucidated completely, but evidence supports a dominant-
negative mechanism.13,14
The p.Gln368Ter variant (rs74315329) is the most com-
mon MYOC variant among populations of European
ancestry.11,12,15 The association between p.Gln368Ter and
POAG has an odds ratio (OR) greater than 10, with the
p.Gln368Ter variant associated with younger age at onset
and greater severity of IOP elevation.16,17 The estimated pen-
etrance of p.Gln368Ter in glaucoma and ocular hypertension
(OHT) has been inconsistent between family studies and
general population-based studies.11,12,15,18-20 There are sev-
eral potential explanations for this inconsistency. Estimates
from family studies may be inflated because of ascertain-
ment bias, aggregation of other genetic factors, and/or con-
founds by common environmental risk factors. Conversely,
estimates from general population-based designs are likely
to be low because of undersampling of cases (especially
more severely affected cases) among volunteer-based
studies.20 Additionally, for both family studies and general
population-based studies, statistical power is typically low
because of the relatively low numbers of p.Gln368Ter carri-
ers.
In this study, we explore the penetrance and association
ofMYOCp.Gln368TervariantwithglaucomaandOHT inwhite
European individualsenrolled in theUKBiobank (UKBB) study
and compare the results with registry-based studies.
Methods
The UKBB project is a large-scale prospective cohort study of
approximately 500000 individuals across the United King-
dom, aged between 40 and 69 years at the time of recruit-
ment (2006-2010). Detailed information on the UKBB study
is available online (http://www.ukbiobank.ac.uk/resources/),
andthegenotypecurationprocess isdescribed inBycroftetal.21
The study was approved by the National Research Ethics
Service Committee NorthWest–Haydock, in accordancewith
the Declaration of Helsinki. Approval was also obtained from
QIMR Berghofer Institute of Medical Research, the Southern
Adelaide Clinical Human Research Ethics Committee of
FlindersUniversity, theUniversity of Tasmania, and theRoyal
VictorianEyeandEarHospital, also inaccordancewith theDec-
laration of Helsinki. Written informed consent was obtained
from all participants.
In theUKBB study, the genotypic datawere imputedwith
IMPUTE4 (Oxford University Innovation), using the Haplo-
typeReferenceConsortium,UK10K, and 1000GenomesPhase
3 referencepanels.Among487409participantspassinggeno-
typing quality control, 409 694 had white British ancestry
based on self-reported race/ethnicity data. We identified
438870 individuals who fell within the same genetic princi-
pal components-based clustering as those who self-reported
white British ancestry, based on the first 2 genetic principal
components (eFigure 1 in the Supplement).
Our previous study showed that the p.Gln368Ter variant
can be imputedwith high accuracy fromgenotyping arrays.17
In this study, the imputation posterior probability for each of
the 3 genotypes (GG [homozygous for thenon-risk allele], AG,
and AA [homozygous for the risk allele]) was used to identify
p.Gln368Ter carriers. We calculated the genotype dosages
based on imputation posterior probability. Because the dos-
age only ranged from 0 to 1.1, there were no p.Gln368Ter ho-
mozygous carriers in our study. For downstream analyses re-
quiring best-guess genotypes, we set the dosage threshold of
heterozygous AG at 0.8.
Asubsetof 112690UKBBparticipantsunderwent IOPmea-
surements at the UKBB Assessment Centre using Reichert
Ocular Response Analyzer (Reichert Technologies);22 the de-
tailed procedure is available online.23 The mean corneal-
compensated IOP (IOPcc;UKBBdata field 5254 and5262) and
meanGoldmann-correlated IOP (IOPg; UKBB data fields 5255
and 5263) for each participantwas calculated at the initial as-
sessment visit, with measurements less than 5 mm Hg or
greater than60mmHgset asmissing.Ocular hypertensionor
high IOP was defined as mean IOPcc of more than 21 mm Hg
(n = 6827 of 84481 [8.1%]).
Key Points
Question How does the penetrance and association of myocilin
(MYOC) gene p.Gln368Ter variant with glaucoma and ocular
hypertension differ across studies ascertained in different ways?
Findings This cross-sectional study found that 48% of
p.Gln368Ter carriers older than 65 years had glaucoma or ocular
hypertension, with an odds ratio for primary open-angle glaucoma
of 6.76 (95% CI, 4.05-11.29) compared with noncarriers. In
registry-based studies, penetrance was very high, with the odds
ratio beingmarkedly increased in individuals with advanced
glaucoma (12.16 [95% CI, 6.34-24.97]) compared with individuals
with nonadvanced glaucoma (odds ratio, 3.97 [95% CI, 1.55-9.75]).
Meaning Our results suggest the penetrance in population-based
studies is higher than previously shown and support the need for
early screening of p.Gln368Ter carriers.
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Among the 438870 participantswith genetic data,we re-
movedparticipantswhowithdrewconsent (n = 10 [<0.01%]).
From the remaining 438860 participants, individuals with
glaucomawere identifiedvia the followingcriteria: they (1)had
an International Classification of Diseases, Ninth Revision
(ICD-9) or Tenth Revision (ICD-10) diagnosis of primary open-
angleglaucoma,otherglaucoma,orglaucoma,unspecified; (2)
reported glaucoma in a survey item inquiring about eye prob-
lems or disorders (UKBBdata field 6148); or (3) reported glau-
comainasurvey itemonself-reportednoncancer illness (UKBB
data field 20002). Individuals with POAG were identified by
an ICD-9or ICD-10diagnosisofPOAG.Amongparticipantswith
IOP measurements, those with IOPcc measurements greater
than 21 mm Hg were defined as having OHT or glaucoma, as
were those individuals identified as having glaucoma. The in-
formation for age at glaucomaonsetwas gathered fromUKBB
data fields 4689 and 20009; field 21022 was regarded as age
at recruitment.
Finally, individuals were selected as healthy control par-
ticipants for glaucoma, POAG, andOHT if they (1) didnothave
other serious eye diseases (UKBBdata field 6148; 26 576 indi-
viduals excluded) and (2) did not have other kinds of glau-
comadiagnosed by ICD-9 or ICD-10 (diagnosed as a glaucoma
suspect or diagnosedwith PACG or secondary glaucoma; 947
individuals excluded). For control participantswithoutPOAG,
6886 individuals with other types of glaucoma were re-
garded as having not-available status. In total, 411 337 UKBB
participants were included in this study. The flowchart illus-
trating selection criteria is shown in eFigure 2 in the Supple-
ment.
Inadditiontoexaminingpopulation-baseddata,weconsid-
ered participants from2 registry-based studies: the Australian
andNewZealandRegistryofAdvancedGlaucoma(ANZRAG)and
theGlaucomaInheritanceStudyinTasmania(GIST).Recruitment
hasbeenpreviouslydescribed.24,25 Inbrief, patientswithglau-
coma fromAustralia andNewZealandhadbeen referred to the
ANZRAGbytheirophthalmologists.ParticipantsintheGISTwere
recruitedfromsurveysdistributedtoophthalmologyclinicsand
advertisementsaroundTasmania.Clinical informationwascol-
lectedbythepatient’streatingophthalmologist.Participantsfrom
ANZRAGandGISTwereconsideredtohaveglaucomaif theyhad
glaucomatousvisual fielddefectsonstandardautomatedperim-
etryandneuroretinal rimthinning (cup-to-disc ratio [CDR]≥0.7
orCDRasymmetry≥0.2). Individualsconsideredtobeglaucoma
suspects hadOHT defined by an IOP greater than 21mmHg or
hadpreperimetricglaucomabasedonglaucomatousappearance
of theopticdisc or thinningor the retinal nerve fiber layerwith
no glaucomatous field changes.
There were 2 arms to the ANZRAG and GIST component.
First, therewas a sequencing-based studywithin theANZRAG
and GIST data sets alone, to estimate the penetrance of
p.Gln368Tervariants. Second,anarray-basedgenome-wideas-
sociation study allowed the estimation of the odds of glau-
coma in a large sample of individuals with cases and control
participants sourced from outside ANZRAG and GIST.
In the sequencing-based study, all participantswith glau-
coma and their relatives in the ANZRAG and GIST registries
underwent Sanger sequencing for MYOC exon 3, as previ-
ously described.26 Participants who were found to be MYOC
p.Gln368TercarrierswereconsideredSangervalidated,andage
at diagnosis was ascertained.
In the array-based study,we selected a total of 3071 unre-
lated participantswith glaucoma from the ANZRAG andGIST
registries and 6750 unscreened control participants from the
BrisbaneAdolescentTwinStudy, theAustralianCancer Study,
a study of inflammatory bowel diseases, and a study of
endometriosis.27-29 The sampleswere genotypedonOmni 1M
(Illumina), OmniExpress (Illumina), or HumanCoreExome
(Illumina)arrays;approximately two-thirdsofcasesweregeno-
typedonHumanCoreExomearrays,with the remainder typed
on arrays with higher single-nucleotide polymorphism den-
sity (Omni 1M and OmniExpress), with a similar proportion
among the control participants.30 Genotype imputation was
performed using Minimac3 through the Michigan Imputa-
tion Server, with the Haplotype Reference Consortium re-
lease 1.1 as the reference panel.
We investigated the effect size of p.Gln368Ter for indi-
vidualswithadvancedglaucoma (n = 1753of 3071 [57.1%]) and
nonadvanced glaucoma (n = 1318 [42.9%]) separately. Indi-
viduals with advanced and nonadvanced glaucoma were de-
fined as previously described.31
Statistical Analysis
Descriptive statistics arepresentedasmeans (SDs) for continu-
ous variables or as numbers (percentages) for categorical vari-
ables. Continuous variables were compared between groups
using analysis of variance, whereas Pearson χ2 or Fisher exact
testswereusedforcategoricalvariables.Weexploredthepreva-
lence of glaucoma and OHT in 4 age groups (younger than 50
years,50-59years,60-65years,andolderthan65years)ofMYOC
p.Gln368Ter carriers.We also investigated the cumulative risk
of glaucomabyage50years, 60years, and65yearsusingaCox
model (adjusted for sexandthe first6geneticprincipal compo-
nents of theUKBB) or theKaplan-Meiermethod (ANZRAGand
GIST).Theassociationbetweenp.Gln368Terdosageanddisease
statuswas estimatedusing logistic regressionadjusted for sex,
age,andthefirst6geneticprincipalcomponents.Tocontrolbias
from familial relationships in association analysis, we used a
relationship-basedpruning strategy inplink toexclude 1mem-
berofeachpairofsamples if thegenomicrelatednesswasgreater
than0.2.32Weused thebasicpackages andsurvival package in
analyses inR (version3.4.1;http://www.r-project.org).Weused
2-tailedP values and an α level of .05. Analysiswas completed
fromSeptember 2017 to July 2018.
Results
Table 1 shows the baseline characteristics of the 411 337UKBB
participants included in this study. Of these, 188 725 partici-
pants (45.9%) were male. The mean (SD) age of participants
was 56.6 (8.0) years, with a mean (SD) IOPcc of 16.1 (3.5) mm
Hg and a mean (SD) IOPg of 15.9 (3.6) mmHg. We observed a
trend that the mean level of IOP increased with age.
Among the 411 337 UKBB participants, 7997 individuals
with glaucoma (1.9%)were identified. A total of 1111 individu-
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als with POAG were identified by an ICD-9 or ICD-10 diagno-
sis of primary open-angle glaucoma.
From411 337UKBBparticipants, itwasestimated that 1046
carried the p.Gln368Ter AG genotype. The minor allele fre-
quency (MAF) of risk allele A of p.Gln368Terwas 1 of 786 par-
ticipants (0.13%), and the observed MAFs were roughly the
same across different age groups. As expected, given the fre-
quency, no AA homozygotes were observed.
TheMYOCp.Gln368Terpenetranceand itsassociationwith
glaucoma and OHT are summarized in Table 2. The pen-
etrance of p.Gln368Ter in glaucomawas estimated to be 7.6%
(n = 79of 1046); in POAG, itwas 1.6% (n = 16of 1046); inOHT,
24.3% (n = 52 of 214); and in OHT or glaucoma combined, it
was estimated to be 30.8% (n = 66 of 214). The odds ratio of
p.Gln368Ter inglaucomawas4.40(95%CI,3.38-5.71); inPOAG,
it was 6.76 (95% CI, 4.05-11.29); in OHT, it was 3.56 (95% CI,
2.53-4.92); and in OHT and glaucoma combined, it was 4.18
(95%CI, 3.05-5.67). For p.Gln368Ter carriers, their IOPccwas
2.04 (95% CI, 1.44-2.64)mmHg higher than in individuals of
GG genotype.
In the UKBB, the age-associated prevalence of glaucoma,
POAG, OHT, and OHT or glaucoma is summarized in Table 3
and theFigure. Inp.Gln368Ter carriersolder than65years, the
prevalence of glaucoma was 15.5% (n = 30); in POAG, it was
4.1% (n = 7); in OHT, 40.0% (n = 20); and in OHT and glau-
coma combined, 48.0% (n = 24).
Wegathered informationonageatglaucomaonset for4915
individuals; the mean (SD) age at diagnosis was 53.5 (10.8)
years. The cumulative risk of glaucoma at 50 years was 2.3%
(95% CI, 1.3%-3.2%). At 60 years, it was 8.1% (95% CI,
6.0%-10.3%), and at 65 years, it was 15.6% (95% CI,
11.7%-19.3%; eTable 1 in the Supplement).
In the sequencing-based study, 174 participants in the
ANZRAG and GIST registries were found to be Sanger-
validated MYOC p.Gln368Ter carriers, including 164 with a
knownageatdiagnosis.Among these 164 individuals (77male
and 87 female), 92 (56.1%) had glaucoma,24 22 (13.4%) were
considered to be glaucoma suspects, and 50 (30.5%)wereun-
affected. The mean (SD) age at glaucoma diagnosis was 53.2
(12.9) years, and theirmean (SD) IOPatdiagnosiswas32.5 (9.5)
mmHg. The penetrance of p.Gln368Ter with respect to glau-
comawas56.1% (n = 92); for awiderdefinition, includingboth
patientswith glaucomaandpatientswhowere glaucoma sus-
pects, the penetrance was 69.5% (n = 114; Table 4).
Table 1. Characteristics of 411 337 UK Biobank Study Participants
Characteristics
Mean (SD)
Age <50 y
(n = 94 164)
Age 50-59 y
(n = 138 395)
Age 60-65 y
(n = 101 322)
Age >65 y
(n = 77 456)
Age, y 45.0 (2.7) 54.8 (2.9) 61.9 (1.4) 66.9 (1.5)
Sex, No. (%)
Male 42 529 (45.2) 60 806 (43.9) 46 539 (45.9) 38 851 (50.2)
Female 51 635 (54.8) 77 589 (56.1) 54 783 (54.1) 38 605 (49.8)
Corneal-compensated
intraocular pressure, mm Hg
15.20 (3.2) 15.78 (3.4) 16.5 (3.6) 16.9 (3.7)
Goldmann-correlated
intraocular pressure, mm Hg
15.38 (3.4) 15.76 (3.6) 16.23 (3.6) 16.38 (3.8)
Table 2. Disease Prevalence, Penetrance, and Risk Effect ofMyocilin (MYOC) Gene p.Gln368Ter Variant
in the UK Biobank
Phenotype
No. (%)
rs74315329 (AG) rs74315329 (GG)
Odds Ratio
(95% CI)a P Valueb
Individuals included
All 1046 (0.3) 410 291 (99.7) NA NA
With intraocular pressure
measurements
214 (0.3) 84 267 (99.7) NA NA
Disease
Glaucoma (n = 1046) 79 (7.6) 7918 (1.9) 4.40 (3.38-5.7) <.001
Primary open-angle
glaucoma (n = 1046)
16 (1.6) 1095 (0.3) 6.76 (4.05-11.3) <.001
Ocular hypertension
(n = 214)
52 (24.3) 6775 (8.0) 3.56 (2.53-4.9) <.001
Ocular hypertension or
glaucoma (n = 214)
66 (30.8) 8015 (9.5) 4.18 (3.05-5.7) <.001
Intraocular pressure
Corneal-compensated
intraocular pressure,
mean (SD), mm Hg
18.10 (4.5) 16.06 (3.5) NA <.001
Goldmann-correlated
intraocular pressure,
mean (SD), mm Hg
17.74 (4.3) 15.92 (3.6) NA <.001
Abbreviation: NA, not applicable.
a In association analysis, relatives are
removed if the genomic relatedness
was greater than 0.2; approximately
7% of individuals are removed
because of this prior to the
statistical test being applied.
bP values are the association
between p.Gln368Ter dosage and
disease status using logistic
regression adjusted for sex, age,
and the first 6 genetic principal
components; a general linear model
was used for intraocular pressure
levels.
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The Figure and eTable 2 in the Supplement present the
age-associated prevalence of glaucoma and suspected glau-
coma among p.Gln368Ter carriers in the ANZRAG and GIST
registry-based studies. The cumulative risk of glaucoma in
MYOC p.Gln368Ter carriers at 50 years was 55.9% (95% CI,
44.1%-67.7%); at age 60 years, it was 80.5% (95% CI,
71.9%-89.1%), and at 65 years, it was 87.1% (95% CI, 79.9%-
94.2%). The cumulative risk of patients being considered to
have glaucoma or be glaucoma suspects was 77.6% (95% CI,
66.9%-88.3%) at age 50 years, 94.4% (95% CI, 89.6%-99.2%)
at age 60 years, and 96.0% (95% CI, 92.1%-99.8%) at age
65 years (eTable 3 in the Supplement). Based on imputed
p.Gln368Ter status, the odds of p.Gln368Ter among
individuals with advanced glaucoma were 12.2 (95% CI,
6.3-25.0), and for those with nonadvanced glaucoma, they
were 3.97 (95% CI, 1.6-9.8).
Discussion
Toourknowledge, this is the largest study toexamine thepen-
etrance and association of theMYOCp.Gln368Ter variantwith
glaucomaandOHTinacohortof individualsofEuropeanances-
tryandcompare itwithdata from2large registry-basedstudies.
We found that p.Gln368Terwas robustly associatedwith glau-
coma,POAG,andOHTandthatitspenetranceincreasedwithage.
The p.Gln368Ter variant was well imputed (with an im-
putation quality score of 93.8%), and the MAF was 0.13% in
theUKBBdata. In this study, theMAFwas similar to those re-
ported from exome sequencing databases (ie, 192 of 126640
[0.15%]) in non-Finnish European individuals in the Genome
AggregationDatabase (http://gnomad.broadinstitute.org/) but
muchhigher thanthat recently reported in theTwinsUKcohort
(MAF, 8 of 12 184 [0.07%]).20 The lower MAF seen in the
TwinsUKcohort suggests that thesetofvolunteersascertained
was biased toward healthy individuals.
In the UKBB study, individuals with POAG or glaucoma
were identified by ICD-9 or ICD-10 diagnosis or self-reported
questionnaires; the prevalence of POAG was estimated at
0.27%,andtheprevalenceofglaucomawasestimatedat 1.94%.
Aprevious studyestimated theprevalence inEuropeof POAG
at2.51%andglaucomaat2.93%.1Previous studies also showed
that 50% of glaucoma cases are undiagnosed.33,34 Because of
the lackof a comprehensive eye examination in theUKBB, the
proportion of individuals with glaucoma or POAG found here
was lower than expected. However, IOP is a key risk factor for
POAG, and the main mechanism of p.Gln368Ter is via eleva-
tionof IOP.10,31,35Thepenetranceandriskeffectofp.Gln368Ter
in OHT serves as a proxy for POAG.20 The prevalence of OHT
(definedas IOPcc>21mmHg) reported in this studywas8.08%,
which is similar to an earlier study.36
Familystudieshaveshownthatp.Gln368Terhadahighpen-
etranceinPOAGandOHT.12,15,18Forinstance,Craigetal15reported
the age-related penetrance of p.Gln368Ter for OHT or POAG as
28of 39 individuals (72%) at age40years and 14of 17 individu-
als (82%)atage65years.Another studybyAllinghametal18ob-
servedthat9of9people(100%)withthep.Gln368Tervarianthad
Table 3. Age-Related Prevalence of Glaucoma
andOcular Hypertension in the UK Biobanka
Age Group, y
No. (%)
P Valuers74315329 (AG) rs74315329 (GG)
Glaucoma
<50 3 (1.3)b 469 (0.5) .12
50-59 19 (5.2) 1817 (1.3) <.001
60-65 27 (10.8) 2555 (2.5) <.001
>65 30 (15.5) 3077 (4.0) <.001
Primary open-angle
glaucoma
<50 1 (0.4) 36 (0.0) .09
50-59 3 (0.9) 216 (0.2) .02
60-65 5 (2.2) 326 (0.3) <.001
>65 7 (4.1) 517 (0.7) <.001
Ocular hypertension
<50 9 (22.0) 715 (4.0) <.001
50-59 12 (15.6) 1730 (6.4) <.001
60-65 11 (23.9) 2172 (9.8) <.001
>65 20 (40.0) 2158 (12.7) <.001
Ocular hypertension
or glaucoma
<50 9 (22.0) 791 (4.4) <.001
50-59 15 (19.5) 1985 (7.3) <.001
60-65 18 (39.1) 2583 (11.7) <.001
>65 24 (48.0) 2656 (15.6) <.001
a Approximately 5% of the individuals are removed because of relatedness prior
to determination of significance; P values are from χ2 test or Fisher exact test
comparing disease prevalence based on p.Gln368Ter genotypes in different
age groups.
bNumber of cases (prevalence).
Figure. Age-Associated Prevalence of Glaucoma, Suspected Glaucoma,
andOcular Hypertension in p.Gln368Ter Risk Allele Carriers
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ANZRAG indicates the Australian and New Zealand Registry of Advanced
Glaucoma; GIST, the Glaucoma Inheritance Study in Tasmania;
UKBB, the UK Biobank.
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elevated IOP, and 7 of 9 individuals (78%) had POAG by age 70
years.18 The current analysis ofANZRAGandGIST registrydata
indicated that the cumulative risk at 65 years oldwas 87.1% for
glaucoma and 96.0% for a combination of glaucoma and sus-
pectedglaucoma,whichwasconsistentwith findings frompre-
vious family-based studies.12,15,18
Fromtheirpopulation-basedstudy,Nagetal20 reportedthat
thepenetranceofp.Gln368TerinrelationtoOHTwas1of8people
(12.5%) in the TwinsUK study and 6 of 31 (19.4%) in the Rotter-
damStudy. The penetrance of p.Gln368Ter for POAGwas 1 of 8
(12.5%) intheTwinsUKstudyand3of31 (9.7%) intheRotterdam
Study. For OHT, our study showed that the penetrance of
p.Gln368Ter (n = 52of214 [24.3%])was lower than in theprevi-
ousfamilystudiesbuthigherthaninthepopulation-basedstudy.
With approximately 100000 participants with IOP mea-
surements, our study provided a more robust estimation of
p.Gln368Ter penetrance in OHT in population-based studies.
However, the number of individuals with POAG was much
lower than expected, given the typical prevalence of POAG in
Europe (2.51%).1 Hence, the true penetrance of p.Gln368Ter
in POAG is likely to be larger than estimated in the UKBB
samples in this analysis. This again may reflect the bias of a
volunteer-based study design.37
We also proposed amethod to calculate the penetrance of
p.Gln368Terbasedonitsoddsratio,MAF,anddiseaseprevalence
(eMethods in the Supplement). According to the proposed
method, if the prevalence of glaucoma was 2.93% and that of
POAGis2.51%inpopulationsolder than40years, thenusingthe
odds ratios and MAF of p.Gln368Ter from the UKBB, the esti-
matedoverall penetranceofp.Gln368Ter for glaucomawasde-
rived to be 10.7% and that of POAGwas derived to be 15.1%.
Thepenetranceofp.Gln368TerwithrespecttoOHTandglau-
comacombined is amore comprehensive indicator. This study
showedthat inp.Gln368Tercarriers, thecumulative riskofOHT
orglaucomawas38.69%atage65years inthepopulation-based
study and 95.96% in glaucoma-based registries; p.Gln368Ter
genotypinghasgreatpotentialforearlyidentificationofindividu-
als at risk for developing these eye diseases19,31,38
Thepenetranceofp.Gln368Terwith respect toglaucoma in
the UKBB data was lower than in the family studies. There are
severalpotentialreasonsforthis.Ontheonehand,estimatesfrom
familystudiesmayhavebeeninflatedbyascertainmentbias.On
theotherhand,thepenetranceingeneralpopulation-basedstud-
iesmaybeunderestimatedbecauseofundersamplingofaffected
individuals.Furthermore, it remainspossiblethataggregatedge-
neticandenvironmental risk factors in family studiesmayhave
ledtoincreasedpenetranceinp.Gln368Tercarriers.Recruitment
basedon familieswithmultiple affected individuals is likely to
lead to an increase in the number of common variants of indi-
viduallysmalleffect (polygenes) ina family,potentially increas-
ingthepenetranceofvariantssuchasp.Gln368Ter.Thissupports
theuseofcascade testing forclose relativeswhoshare thesame
genetic background.
Limitations
This studyhassome limitations.Thegenotypesofp.Gln368Ter
in the UKBB study are based on best-guess imputed geno-
types. Reassuringly, our previous study presented evidence
that the p.Gln368Ter variant could be imputed with high
accuracy.17 Thus, the imputed genotype is unlikely tomake a
meaningful difference in our results.
Another limitation of the UKBB study is that some indi-
viduals with glaucoma were defined by self-reported ques-
tionnaires,which could lead to recall bias.However, our study
is one of the largest studies to investigate the penetrance and
risk effect of p.Gln368Ter inOHT,which could serveas aproxy
for glaucoma or POAG.20 Furthermore, individuals with
glaucoma who also have other eye disorders may be less
likely to participate theUKBBproject, comparedwithhealthy
individuals,37whichcould leadtoa lowerestimatedpenetrance
of p.Gln368Ter in glaucoma. Moreover, in the ANZRAG and
GIST registries, the controlswere genotypedondifferent plat-
forms. As a sensitivity analysis,we substituted theAustralian
control participants for controls from the UKBB data; our re-
sults were essentially unchanged.
Finally, someindividualswithhighIOPpresent in theUKBB
cohortmaybe takingmedicationsorhaveundergoneophthal-
mic surgery to reduce their IOP levels. In our sensitivity analy-
sis to adjust for the change in IOP postmedication, when we
added 25% to the measured IOP levels for individuals taking
IOP-loweringmedications,39,40theresultantoddsratiosandpen-
etrancewith respect to OHT increased only slightly.
Conclusions
OurstudysuggeststhattheMYOCp.Gln368Tervarianthasahigh
penetranceinOHTandglaucoma.Genetictestingforp.Gln368Ter
could help identify individuals who at greater risk of develop-
ing glaucomaanddirect them to early screening and appropri-
atemanagement.
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